O
LSB

OrbiMed’s LakeShore Biopharma LSB Stock Holding History

OrbiMed’s Portfolio LSB Stock Details LSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-54,799
Closed -$55.9K – 127
2025
Q2 		$55.9K Sell
54,799
-85,629
-61% -$108K ﹤0.01% 102
2025
Q1 		$344K Hold
140,428
– – 0.01% 110
2024
Q4 		$486K Buy
+140,428
New +$412K 0.01% 117
2024
Q3 		– Sell
-140,428
Closed -$910K – 134
2024
Q2 		$910K Sell
140,428
-13,015
-8% -$106K 0.02% 111
2024
Q1 		$1.1M Sell
153,443
-170,188
-53% -$867K 0.02% 110
2023
Q4 		$1.65M Sell
323,631
-130,511
-29% -$751K 0.03% 100
2023
Q3 		$3.63M Buy
454,142
+24,295
+6% +$280K 0.08% 104
2023
Q2 		$5.93M Buy
429,847
+1
+0% +$15 0.11% 97
2023
Q1 		$6.88M Buy
+429,846
New +$21.8M 0.14% 94

Other funds holding LSB

Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

OrbiMed's LSB Position: Q3 2025 in Review

OrbiMed sold out of LakeShore Biopharma (LSB) in Q3 2025, closing a stake of 54,799 shares — an estimated $55.9K sold.

OrbiMed first reported a position in LSB in Q1 2023 and held it in 9 quarters. The position peaked at $6.88M in Q1 2023. 1 fund tracked by Wall St. Rank holds LSB as of Q3 2025.

  • OrbiMed reported no remaining LakeShore Biopharma position as of Q3 2025 after selling out during the quarter.
  • OrbiMed sold 54,799 LakeShore Biopharma shares in Q3 2025, an estimated $55.9K.
  • OrbiMed first reported a position in LakeShore Biopharma in Q1 2023 and held it in 9 quarters.
  • OrbiMed's LakeShore Biopharma position peaked at $6.88M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held LakeShore Biopharma as of Q3 2025.

Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.